ZIMLAB Releases Q2 & H1 FY26 Earnings Call Transcript, Discusses EU-GMP Remediation & H2 FY26 Outlook
ZIMLAB released its Q2 & H1 FY26 earnings call transcript, detailing improved sequential financials with ₹88.7 crore revenue and reduced loss. The company is actively addressing EU-GMP remediation by March 2026 and expects FY26 revenues to match FY25.
The EU-GMP suspension is a critical issue impacting regulated market access and growth, requiring significant remediation efforts and strategic site transfers. While the company showed sequential financial improvement and has a plan to mitigate the impact, the long-term resolution of the EU-GMP status is crucial for unlocking full value and future revenue growth.
The company reported sequential improvement in revenue and profitability, with a narrowed net loss and increased EBITDA margin. Proactive measures for EU-GMP remediation and business continuity, including site transfers and alternate certifications, are underway with a clear timeline. Management expects strong H2 FY26 performance to match previous year's revenue, indicating resilience and strategic execution despite ongoing regulatory challenges.
* Zim Laboratories Limited has released the transcript of its Q2 & H1 FY26 Earnings Conference Call, which was held on Friday, 14th November 2025. * The company’s highest strategic priority is EU-GMP remediation, with an aggressive target to complete the audit by March 2026. Supplies are expected to resume by Q1 or Q2 financial year 2027. * Proactive steps for business continuity include reviewing orders from other emerging markets and initiating site transfer projects for key products like Tamsulosin + Dutasteride (expected commercial supplies within 6 months) and Dimethyl Fumarate and Azithromycin suspension to EU and MHRA-approved facilities. * For Q2 FY26, total operating income stood at ₹88.7 crore, marking a 23.6% sequential increase. EBITDA improved to ₹7.8 crore, with margins rising to 8.8% from 7.9% in Q1 FY26. * The net loss narrowed to ₹0.4 crore, compared to a loss of ₹1.9 crore in the previous quarter. * The Pharmaceutical business contributed 83% of total revenue at ₹73.2 crore, growing 30.7% quarter-on-quarter. The Nutra segment accounted for 17% at ₹15.5 crore, with a decline primarily due to deferred domestic institutional orders, which are expected to materialize in Q3 and Q4. * Export revenue was ₹72.8 crore, a 21% sequential improvement, while domestic business contributed ₹12.7 crore. * The NIP and OTF portfolio contributed ₹8.1 crore, and licensing income was ₹2.9 crore for Q2 FY26. * The company invested ₹7.6 crore in R&D during the quarter. * Management expects FY26 revenues to be broadly in line with FY25 revenues, with a strong order book for Q3 and a historical trend of 60% of business in the second half. * The EU-GMP non-compliance related to a
What to do with a filing like this
Zim Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zim Laboratories Limited. Read the original for the full detail.